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KEY MESSAGES 1 
 2 
 In this cohort study including more than 500 000 individuals, insulin resistance measured 3 
as the logarithmized triglyceride glucose product (TyG index) mediated part of the effect 4 
of overweight and obesity on risk of cancers of the pancreas, rectum, colon, kidney, and 5 
liver. 6 
 In contrast, TyG index did not mediate the risk of cancers of the endometrium, ovary and 7 
breast. 8 
 Our results confirm a promoting role of insulin resistance in the pathogenesis of 9 
gastrointestinal cancers. 10 
 Although often claimed, our results provide limited evidence that insulin resistance 11 





Background: The role of insulin resistance as a mediator in the association of body mass 3 
index (BMI) with site-specific cancer risk has, to our knowledge, never been systematically 4 
quantified. 5 
Methods: Altogether 510 471 individuals from six European cohorts with a mean age of 43.1 6 
years were included. We used the triglyceride glucose product (TyG index) as a surrogate 7 
measure for insulin resistance. We fitted Cox models, adjusted for relevant confounders, to 8 
investigate associations of TyG index with ten common obesity-related cancers, and quantified 9 
the proportion of the effect of BMI mediated through TyG index on the ln(HR) scale. 10 
Results: During a median follow-up of 17.2 years, 16 052 individuals developed obesity-11 
related cancers. TyG index was associated with the risk of cancers of the kidney (hazard ratio 12 
(HR) per one standard deviation increase 1.13, 95% confidence interval: 1.07-1.20), liver (1.13, 13 
1.04-1.23), pancreas (1.12, 1.06-1.19), colon (1.07, 1.03-1.10), and rectum (1.09, 1.04-1.14). 14 
Substantial proportions of the effect of BMI were mediated by TyG index for cancers of the 15 
pancreas (42%), rectum (34%), and colon (20%); smaller proportions for kidney (15%) and 16 
liver (11%). Little or no mediation was observed for breast (postmenopausal), endometrial, and 17 
ovarian cancer. Results were similar for males and females, except for pancreatic cancer 18 
where the proportions mediated were 20% and 91%, respectively. 19 
Conclusions: The TyG index was associated with increased risk of cancers of the digestive 20 
system and substantially mediated the effect of BMI, suggesting that insulin resistance plays 21 
a promoting role in the pathogenesis of gastrointestinal cancers. 22 
 23 





A large body of epidemiological evidence has established that excess body weight, 3 
both overweight (body mass index (BMI) of 25.0 to 29.9 kg/m²) and obesity (BMI ≥30.0 kg/m²), 4 
is a major risk factor for many cancer forms1–8. In 2004, Calle and Kaaks9 proposed three 5 
biological candidate mechanisms potentially mediating the association of excess body weight 6 
with cancer risk: (i) increased bioavailability of steroid hormones and alterations in sex 7 
hormone metabolism; (ii) adipokine pathophysiology and systemic (subclinical) inflammation; 8 
and (iii) insulin resistance and bioavailability of insulin-like growth factor I (IGF1). The pathways 9 
triggering the effect of excess weight might differ between cancer sites. While in cancers of the 10 
female reproductive organs the effect of BMI might be largely mediated by increased oestrogen 11 
levels, there is mounting evidence for a substantial mediation through pathways connected to 12 
insulin resistance for some gastrointestinal cancers9–11. There are several mechanistic studies 13 
investigating these pathways (i.e. in vitro and animal models)11. In recent years, also 14 
epidemiological studies with prospective designs addressed this question of mediation for 15 
some selected cancer sites12–15. 16 
The logarithmized product of fasting levels of triglycerides and glucose (denoted TyG 17 
index) has been suggested to be a simple measure of insulin resistance16. Both lipotoxicity and 18 
glucotoxicity play crucial roles in insulin resistance modulation that are reflected in the TyG 19 
index17,18. The TyG index is highly correlated with the euglycemic-hyperinsulinemic clamp test, 20 
the gold standard for determining insulin resistance (Pearson correlation coefficient ρ=-0.68 21 
between TyG index and total glucose metabolism rates as determined by the clamp 22 
procedure19), and thus has validity similar to the frequently used homeostatic model 23 
assessment (HOMA) insulin resistance (IR) index (ρ=-0.77 between HOMA-IR index and total 24 
glucose metabolism rates as determined by the clamp procedure19). Thus, due to its easy 25 
availability and cost-effectiveness, the TyG index is a promising surrogate measure for insulin 26 
resistance in large-scale epidemiological studies. 27 
6 
 
Given the well-established association of obesity with cancer risk of various sites and 1 
that one of the hypothesized links is insulin resistance, both an association of TyG index with 2 
the risk of obesity-related cancers as well as substantial mediation of the BMI effect through 3 
the parameter TyG index, seem biologically plausible. However, despite the TyG index’ 4 
simplicity, neither its association with cancer risk nor its contribution to the effect of BMI on 5 
cancer risk has been previously investigated. The aim of this study was (i) to quantify the effect 6 
of TyG index on the risk of obesity-related cancers, and (ii) to estimate the proportion of the 7 
effect of BMI on cancer risk that is mediated through the TyG index, in a large, pooled 8 




Data source and selection criteria 13 
We used data from the Metabolic syndrome and Cancer project (Me-Can) 2.0, a pooling 14 
of six population-based cohorts; three Norwegian cohorts (Oslo study I, Norwegian Counties 15 
Study (NCS), the 40-year programme (40-y)), two Swedish cohorts (Västerbotten Intervention 16 
Programme (VIP), Malmö Preventive Project (MPP)), and one Austrian cohort (Vorarlberg 17 
Health Monitoring and Prevention Programme (VHM&PP)). Me-Can 2.0 is a follow-up project 18 
from Me-Can 1.0, which has been described in detail elsewhere20, and includes additional 19 
individuals, more events and a longer follow-up as compared to Me-Can 1.0. The study was 20 
approved by research ethics committees in the respective countries. 21 
Data on height, weight, smoking status and serum and plasma levels of glucose and 22 
triglycerides (including fasting time before sampling) have been collected at health 23 
examinations in all cohorts. Blood glucose values obtained from whole blood, as in the MPP 24 
cohort, were converted into the equivalent of serum/plasma levels by increasing the whole 25 
blood value by 11%21. BMI was calculated directly from weight and height records (weight 26 
(kg)/height (m)²) measured by medical staff. The TyG index was calculated as ln[triglycerides 27 
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(mg/dl) x blood glucose (mg/dl)/2]16. Diabetic status was further assessed in a questionnaire 1 
that was given to all participants, except for the VHM&PP cohort. 2 
Out of overall 843 531 individuals, we excluded participants with missing or implausible 3 
information on BMI, triglycerides, glucose, smoking status and fasting time before 4 
measurement (n=321 464). The majority of these exclusions (93%) arose because glucose 5 
was not measured in the NCS and 40-year cohorts throughout all years. Glucose 6 
measurements were only available for 68% and 34% of participants in these cohorts, 7 
respectively. A total of 216 cases were excluded because information on the date of cancer 8 
diagnosis, death, or date of emigration was inconsistent. In addition, individuals with any record 9 
of cancer before (n=6045) or up to twelve months after study entry (n=1674) or a follow-up 10 
time less than twelve months (n=3661) were excluded, thereby reducing the possibility of 11 
reverse causation (i.e. parameters of interest affected by undiagnosed cancer). Thus, there 12 
were 510 471 individuals in our final analysis. 13 
 14 
Follow-up and endpoint assessment 15 
To obtain information on cancer diagnoses, date of death (for all cohorts) and date of 16 
migration (not available for the VHM&PP), each cohort was linked to their respective national 17 
Cancer Registry, Cause of Death Registry, and Population Registry. Cancer incidence, death 18 
and migration information was followed until December 31, 2012 for the Norwegian cohorts 19 
and until December 31, 2014 in all other cohorts. Incident cancers were grouped into relevant 20 
cancer types according to the International Classification of Diseases, seventh and tenth 21 
revision (ICD-7, ICD-10). We investigated those cancer sites where the evidence of 22 
association to BMI is strong or highly suggestive according to the current viewpoint of the IARC 23 
working group6 and a recent umbrella review7: oesophagus (adenocarcinoma), colon, rectum, 24 
liver, gallbladder, pancreas, endometrium, ovary, breast (postmenopausal; defined as cancers 25 
diagnosed at the age of 60 years and older22), and kidney (renal cell carcinoma). Participants 26 
were followed from one year after study entry until the earliest of first cancer diagnosis (any 27 




Statistical analysis 2 
In our statistical analysis, we used baseline values measured at the first health 3 
examination as exposure and adjusting variables. We tabulated baseline characteristics both 4 
overall, and stratified by TyG index quintiles. In a linear model, we regressed TyG index on 5 
BMI, adjusting for baseline age, sex, smoking status, fasting status, cohort, and decade of 6 
birth. We estimated hazard ratios (HRs) for TyG index levels with risk of incident cancer using 7 
Cox proportional hazards regression models adjusted for baseline age, sex, smoking status, 8 
fasting status, cohort, decade of birth, and with and without adjustment for BMI category 9 
according to the WHO classification23, using age as the underlying time variable, with entry 10 
time defined as the participant’s age one year after baseline, and exit time as the earliest of 11 
first cancer diagnosis (any site, including those not investigated here), death, emigration, or 12 
end of follow-up. To calculate p-values for trend over quintiles (with cut-off levels determined 13 
separately for each sex, cohort, and fasting time category), the Wald test of a linear association 14 
of a value’s quintile (1-5) with cancer risk was used. Interaction effects between sex and TyG 15 
index were evaluated by including the respective multiplicative term in the Cox models. 16 
To assess mediation and to estimate total, direct, and indirect effects between BMI, 17 
TyG index levels and cancer risk, we used the 2-stage regression method proposed by 18 
VanderWeele24. First, we fitted a linear regression model for the mediator TyG index, 19 
conditional on the exposure BMI and covariates baseline age, sex, smoking status, fasting 20 
status, cohort, and decade of birth. Secondly, we fitted a Cox proportional hazards regression 21 
model for cancer risk on BMI, TyG index, and the same covariates as in the model above. 22 
Finally, we estimated the desired effects combining the coefficients of these two regression 23 
models as described by VanderWeele24. 24 
This method is developed in the counterfactual framework and gives estimates of the 25 
natural direct and natural indirect effects which allow for decomposition of the total effect into 26 
natural direct and indirect effects. In the context of our main analysis estimating risk changes 27 
per 5 kg/m2 increase in BMI, the natural direct effect hazard ratio compares the cancer risk in 28 
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individuals showing a certain reference BMI with individuals whose BMI is 5 kg/m2 higher, if, 1 
also in the group with the higher BMI, the TyG index had been set to the level that would have 2 
been observed if the individuals had the reference BMI. The natural indirect effect hazard ratio 3 
quantifies the change in cancer risk in individuals if the TyG index would have been changed 4 
from the level which was actually observed to the level which would have been observed if the 5 
individuals had a 5 kg/m2 lower BMI. Detailed definitions of these effects can be found 6 
elsewhere25,26. 7 
Since we found no interaction between BMI and TyG index (Table S1, column 2), we 8 
did not include exposure-mediator interaction terms in our final models. The contribution of the 9 
natural indirect effect to the total effect of BMI was calculated on the ln(HR) scale since HRs 10 
are additive on this scale. Ninety-five percent confidence intervals (CIs) were computed by 11 
stratified bootstrap using 2000 replications with strata for sex, smoking status, fasting status, 12 
cohort, and decade of birth. We assessed mediation by treating BMI both as a continuous and 13 
a categorical variable (according to the WHO classification underweight (BMI<18.5), normal 14 
weight (BMI 18.5-24.9), overweight (BMI 25.0-29.9), and obesity (BMI≥30.0)). We repeated 15 
this analysis restricted to individuals with a fasting status of 8h or more, and to individuals free 16 
of diabetes at baseline (i.e. self-report to be non-diabetic and glucose value in the normal 17 
range). For female VHM&PP participants, data on hysterectomies were available. As 18 
sensitivity analysis, we repeated the analysis for endometrial cancer in the VHM&PP cohort, 19 
excluding women undergoing a hysterectomy before baseline or within 12 months after 20 
baseline, and treating hysterectomy as a censoring event. In models including BMI as a linear 21 
term, we restricted analyses to participants with a BMI≥18.5 (i.e. no underweight) since the 22 
assumption of a log-linear association of BMI with cancer risk was violated in the underweight 23 
range for some cancer sites. 24 
We checked if the proportional hazards assumption was fulfilled for the Cox regression 25 
models, by calculating the Pearson correlation coefficient between transformed survival time 26 
and the scaled Schoenfeld residuals. Only for cancers of the colon and rectum we detected 27 
deviations of proportional hazards for the variable sex. Table S2 shows analyses for males 28 
10 
 
and females separately. Although total effects of BMI were larger for men than for women (a 1 
finding already reported by Bhaskaran et al.5), the proportion mediated was similar to the 2 
results of our main analysis. 3 
To provide valid estimates of the natural direct and indirect effects, the method we used 4 
requires as a first assumption that the outcome is relatively rare (i.e. cumulative incidence 5 
≤15%). In our study, the cumulative incidence of all cancers investigated combined was about 6 
12%, and much less for single cancer sites. Secondly, it relies on four non-confounding 7 
assumptions; we have to assume that there is no unmeasured confounding of (i) the exposure-8 
mediator, (ii) the exposure-outcome, and (iii) the mediator-outcome association; finally, for 9 
effects to be identifiable, we have to assume that (iv) there is no exposure-induced mediator-10 
outcome confounding at all (even if known and measured, natural effects cannot be 11 
identified)26–28. 12 
In particular, the “cross-world counterfactual independence” assumption, which denies 13 
exposure-induced mediator-outcome confounding, has to be met26,28,29. In contrast to the 14 
natural direct effect, this assumption is not required for estimation of the controlled direct 15 
effect28. Therefore, we also calculated controlled direct effects to verify the robustness of our 16 
results. This was done by fixing the mediator (TyG index) at certain values (specifically the first 17 
quartile, the median, and the third quartile) and estimating controlled direct effects for these 18 
values of the mediator in models allowing for exposure-mediator interaction26,30. HRs of 19 
controlled direct effects were comparable to natural direct effects for all cancer s ites 20 
investigated (Table S1). 21 
Finally, we compared associations of BMI with cancer risk (conditioning on the same 22 
covariates as listed above), both adjusted and unadjusted for TyG index, also known as the 23 
difference method for mediation analysis31. 24 






Study population 1 
Out of a total of 510 471 study participants, 213 372 (41.8%) individuals originated from 2 
the Norwegian cohorts, 173 538 (34.0%) from the Austrian cohort, and 123 561 (24.2%) from 3 
the Swedish cohorts. The mean age at baseline was 43.1 (SD = 10.6) years, and 257 968 4 
(50.5%) individuals were males. Mean (SD) values of BMI [kg/m2], glucose [mmol/l], 5 
triglycerides [mmol/l], and the TyG index [ln(mg²/(2*dl²))] were 25.2 (4.0), 5.3 (1.2), 1.6 (1.1), 6 
and 8.6 (0.6), respectively (Table 1). 7 
Over a median follow-up time of 17.2 years (i.e. a total of 9 735 122 person-years), 8 
16 052 obesity-related cancers were recorded. 9 
 10 
TyG index and baseline characteristics 11 
Table 2 shows the distribution of BMI, sex, baseline age, smoking status, and fasting 12 
status, stratified by quintiles of TyG index. TyG index and BMI showed a positive linear 13 
association. An increase in BMI of 5 kg/m² was associated with a 0.24 unit increase in TyG 14 
index (R2=0.26) after adjustment for relevant covariates. 15 
 16 
TyG index and risk of cancer 17 
When TyG index was treated as a linear term in the statistical model (Table 3, columns 18 
3 to 4), TyG index was associated with the risk of incident cancer of the kidney (renal cell) 19 
(hazard ratio (HR) per one standard deviation increase 1.13, 95% CI: 1.07 to 1.20), liver (1.13, 20 
1.04 to 1.23), pancreas (1.12, 1.06 to 1.19), colon (1.07, 1.03 to 1.10), and rectum (1.09, 1.04 21 
to 1.14), adjusting for relevant confounders including BMI (Model 2). The corresponding HR 22 
for the combination of cancers of all digestive organs (oesophagus (adenocarcinoma), colon, 23 
rectum, liver, gallbladder, and pancreas) was 1.09 (1.06 to 1.11). Sex did not modify the 24 
association of TyG index with risk of cancer for any site. However, there was a trend towards 25 
an interaction (p=0.064) for pancreatic cancer (HR in males: 1.08 (1.00 to 1.16), HR in females: 26 
1.19 (1.09 to 1.31)). For cancers of the female reproductive organs, i.e. endometrium, ovary, 27 
and breast (postmenopausal; i.e. age at cancer diagnosis ≥60 years), no linear associations 28 
12 
 
of TyG index with risk could be observed, neither individually, nor combined (1.03, 0.99 to 1 
1.06). The quintile analyses of the association between TyG index and cancer risk (Table 3, 2 
columns 5 to 10) provided similar results, with small discrepancies for cancers of the liver and 3 
endometrium. 4 
 5 
BMI and risk of cancer mediated by TyG index 6 
As expected, BMI was associated with an increased risk of all investigated cancer sites 7 
(Table 4). For cancers of the colon, breast (postmenopausal), endometrium, and kidney (renal 8 
cell), the increase in risk with rising BMI was monotonic over all BMI categories, while the other 9 
cancer forms revealed a J-shaped association with BMI, with normal weight being associated 10 
with the lowest risk (Table 5). 11 
When including BMI as a linear term (per 5 kg/m² increase) in mediation analyses 12 
adjusted for relevant confounders and restricted to individuals with BMI values ≥18.5 (Table 13 
4), substantial proportions of the effect of BMI were mediated by TyG index for cancers of the 14 
pancreas (42% of a total effect (HR, per 5 kg/m² increase) of 1.11 (1.03 to 1.20)), rectum (34% 15 
of a total effect of 1.09 (1.03 to 1.15)), colon (20% of a total effect of 1.14 (1.10 to 1.19)), and 16 
cancers of all digestive organs combined (22% of a total effect of 1.16 (1.13 to 1.19)). Smaller 17 
proportions where mediated for cancers of the kidney (renal cell) (15% of a total effect of 1.36 18 
(1.27 to 1.44)) and the liver (11% of a total effect of 1.48 (1.33 to 1.63)). For adenocarcinomas 19 
of the oesophagus and cancers of the gallbladder – the two cancer types with the lowest 20 
number of cases - the proportions mediated were 7% of a total effect of 1.48 (1.23 to 1.73) and 21 
16% of a total of 1.30 (1.14 to 1.46), respectively, with the null effect contained in the 95% CIs 22 
for proportions mediated, however. Results were similar for men and women with the exception 23 
of pancreatic cancer (proportion mediated in males: 20% of a total effect of 1.17 (1.05 to 1.31), 24 
proportion mediated in females: 91% of a total effect of 1.07 (0.97 to 1.17)). The effect of BMI 25 
on cancer risk was mediated by TyG index to a much lesser degree (specifically, natural 26 
indirect effects ≤1.01) for cancers of the female reproductive organs (i.e. breast 27 
13 
 
(postmenopausal), endometrium, ovary,). Figure 1 illustrates the different mediation patterns 1 
for gastrointestinal cancers vs. cancers of the female reproductive organs. 2 
When including BMI as a categorical term according to the WHO classification in the 3 
mediation analyses (Table 5), increased cancer risk of overweight and obese individuals was 4 
mediated by TyG index for cancers of the rectum, pancreas, colon, kidney (renal cell), and 5 
liver. The increased risk of underweight (BMI<18.5) was not mediated by TyG index. 6 
Additionally, we restricted our analyses to individuals with a fasting status of 8h or more, 7 
and to participants who reported to be free of diabetes at baseline. The results were similar to 8 
our findings in the full study population (Tables S3 and S4). Incorporating data on 9 
hysterectomies in the analysis for endometrial cancer in the VHM&PP cohort, left the results 10 
virtually unchanged (HRs of 1.50 (1.36 to 1.66), 1.03 (1.00 to 1.07), and 1.46 (1.31 to 1.61) for 11 
total, natural indirect, and direct effects when ignoring information on hysterectomies vs. HRs 12 
of 1.51 (1.36 to 1.65), 1.03 (1.00 to 1.07), and 1.46 (1.31 to 1.62) when treating hysterectomy 13 
as censoring event). 14 
The findings of the mediation analysis were confirmed in separate analyses using the 15 
traditional difference method for mediation analysis. Table S5 shows that additionally adjusting 16 
for TyG index noticeably attenuated the association of BMI with cancers of the oesophagus, 17 
colon, rectum, liver, gallbladder, pancreas, and kidney, while this was not the case for the 18 




In this large prospective cohort study, TyG index was associated with cancers of the 23 
digestive organs (colon, rectum, liver, and pancreas) and the kidney (renal cell), and a 24 
substantial fraction of the effect of BMI on cancer risk was mediated by the TyG index. In 25 
contrast, such mediation was not observed for cancers of the female reproductive organs 26 
(endometrium, ovary, and breast (postmenopausal)). While for both triglycerides and glucose, 27 
associations with cancer risk have been demonstrated33–36, attempts to relate the TyG index, 28 
14 
 
a surrogate measure for insulin resistance, to cancer risk, have to our knowledge never been 1 
undertaken before. 2 
Which biological mechanisms link excess body weight with cancer risk is debated9–11. 3 
Obesity results in alterations in sex hormone metabolism, chronic (subclinical) inflammation, 4 
and increased circulating insulin levels, the latter of which results in increased levels of free or 5 
bioactive IGF1. All these three consequences of obesity are known to induce mechanisms that 6 
promote carcinogenesis. According to the sex hormone hypothesis, the insulin-IGF hypothesis, 7 
and the inflammation and adipokine hypothesis, these pathways are mediators in the 8 
association of increased BMI with cancer risk11. However, the exact contributions of these three 9 
pathways to the positive association of BMI and cancer risk among different cancer sites are 10 
still incompletely understood. 11 
Considering that TyG index has been shown to be a valid surrogate measure of insulin 12 
resistance with a validity comparable to the frequently used HOMA insulin resistance index19, 13 
treating the TyG index as a mediator in the association of BMI with cancer risk seems 14 
biologically plausible. Our results support the insulin-IGF hypothesis for cancers of the 15 
digestive organs and the kidney; in particular when considering that (i) reducing complex 16 
conditions to single measures (as introduced by capturing insulin resistance by the TyG index) 17 
and (ii) using only one measurement at a single time-point in life, thereby ignoring whole 18 
lifetime trajectories (and thus cumulative effects), in general lead to an underestimation of 19 
indirect effects26,37, which would mean that the true contribution of the insulin-IGF pathway to 20 
the BMI effect on cancer risk is likely even higher. On the other hand, the near absence of any 21 
mediation through TyG index for cancers of the female reproductive organs provides an 22 
indirect support of the sex hormone hypothesis for these cancers. 23 
Most of our results are in line with existing literature9–12. However, for breast and 24 
endometrial cancer, associations of fasting insulin levels and HOMA-IR score with cancer risk 25 
have been reported13,14,38,39, in contrast to our results utilizing the TyG index as a measure of 26 
insulin resistance. Reasons for these discrepancies might be that the TyG index captures 27 
different aspects of insulin resistance than insulin or HOMA-IR, and, particularly, that there are 28 
15 
 
marked differences in the age distribution of the study cohorts at baseline. In the studies of 1 
Hvidtfeldt et al.13 and Gunter et al.14 on postmenopausal breast cancer and Gunter at al. on 2 
endometrial cancer38, using data of the Women’s Health Initiative, the median age at 3 
measurement of insulin and HOMA-IR was beyond 65 years, whereas in our study the median 4 
age at measurement of TyG index was 41.5 years. This huge age difference combined with 5 
differently selected populations makes a comparison between these studies very difficult. In 6 
addition, regarding postmenopausal breast cancer, the age cut-off (we defined cancer 7 
occurring at 60 years and later as postmenopausal) is crucial for the strength of the association 8 
of breast cancer risk with obesity. 9 
Strengths of this study include the large sample size from six European population-10 
based cohorts, long follow-up and use of national cancer registries ensuring a virtually 11 
complete capture of cancer cases. Furthermore, in our study we applied a new analytic tool 12 
for estimating mediating effects originating from the counterfactual framework. Traditional 13 
approaches to mediation analysis typically involve the comparison of Cox models with and 14 
without adjustment for the mediator. Such an approach is limited, most importantly because 15 
the estimates do not have a causal interpretation and are not mathematically consistent26,40. 16 
Although the new counterfactual approaches are greatly preferably to the traditional ones, for 17 
the purpose of comparison, we also performed such a traditional analysis and obtained very 18 
similar results. 19 
Limitations of our study include the lack or limited availability of complete data on 20 
covariates other than the ones included in the analyses that potentially may have influenced 21 
the results, like information on lipid-lowering and/or antidiabetic medication, alcohol 22 
consumption, physical activity, and female reproductive factors such as parity, age at first birth, 23 
or postmenopausal hormone therapy. Furthermore, we did not have measurements of 24 
parameters of inflammation. Since evidence suggests that obesity-induced inflammation might 25 
be one of the underlying mechanisms of insulin resistance in obese individuals41,42, not having 26 
taken the confounding effect of inflammation into account might have led to an overestimation 27 
of the estimated indirect effect through the insulin resistance pathway. 28 
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Other limitations are the different protocols for measurement of triglycerides and 1 
glucose applied in the single cohorts, the lack of information on abdominal obesity, body shape, 2 
or body fat proportion, and insufficiently detailed data to investigate potentially important 3 
differences between cancer subtypes (e.g. breast cancer by receptor status 43, microsatellite 4 
stable vs. instable colorectal cancer44). Different composition of subtypes could explain slightly 5 
different effect estimates of BMI for these cancers in our study compared to other literature5,6. 6 
For liver cancer, the lower prevalence of hepatitis in our study region, a strong risk factor for 7 
liver cirrhosis and liver cancer, may explain why we observed quite a strong association of 8 
obesity with risk of liver cancer compared to other sources5,8. 9 
We did not include further obesity-related cancer sites, such as lymphoma or 10 
leukemia5,8, into our analyses because insulin resistance as a biological mechanism has been 11 
predominately discussed for gastrointestinal cancers and cancers of the female reproductive 12 
organs11. 13 
In conclusion, we showed that a higher TyG index is associated with increased risk of 14 
cancers of the digestive organs (colon, rectum, liver, and pancreas) and the kidney (renal cell), 15 
and that a substantial fraction of the effect of increased BMI on the risk of these cancers can 16 
be explained via the TyG index pathway. In contrast, this does not hold true for obesity-related 17 
cancers of the female reproductive organs (endometrium, ovary, and breast 18 
(postmenopausal)). As TyG index is indicative of insulin resistance, our findings support the 19 
insulin-IGF hypothesis for cancers of the digestive organs and the kidney; i.e. insulin and 20 
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FIGURE LEGEND 1 
 2 
Figure 1. Total, natural indirect (TyG mediated), and direct effects of continuous BMI on cancer 3 
risk of digestive organs (oesophagus, colon, rectum, liver, gallbladder, and pancreas) vs. 4 
female reproductive organs (endometrium, ovary, and breast (postmenopausal)) 5 
HR = hazard ratio; BMI = body mass index.  6 
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Table S1. Comparison of natural direct and controlled direct 1 
effects of continuous BMI on cancer risk, stratified by cancer site 2 



















































































































































































































































































































* HRs (per 5 kg/m² increase for BMI; per 5 kg/m2 * 1 SD of TyG index for the interaction term BMI*TyG 1 
index) from Cox models regressing cancer risk on BMI, TyG index, the multiplicative interaction term 2 
BMI* TyG index, baseline age, sex, smoking status, cohort, and decade of birth, with attained age as 3 
the underlying time scale. Analyses were restricted to participants with a BMI≥18.5 (i.e. no underweight).  4 
TyG index Q1 was at 8.18 ln(mg²/(2*dl²)). TyG index median was at 8.55 ln(mg²/(2*dl²)). TyG index Q3 5 
was at 8.98 ln(mg²/(2*dl²)). 6 
†HRs (per 5 kg/m² increase) were estimated according to the 2-stage regression method proposed by 7 
VanderWeele, adjusted for baseline age, sex, smoking status, cohort, and decade of birth, with attained 8 
age as the underlying time scale. Analyses were restricted to participants with a BMI≥18.5 (i.e. no 9 
underweight). 10 
‡Adenocarcinomas were identified via information on morphology (ICD-O-3 morphologic key). 11 
§Digestive organs combined include the following sites: oesophagus (adenocarcinoma), colon, rectum, 12 
liver, gallbladder, and pancreas. 13 
HR = hazard ratio; BMI = body mass index; CI = confidence interval; ICD = International Classification 14 
of Diseases; SD – standard deviation; Q1 – first quartile; Q3 – third quartile. 15 
  16 
28 
 
Table S2: Decomposition of the total effect of continuous BMI on 1 
cancer risk into natural direct and indirect effect mediated by the 2 
TyG index for cancers of the colon, cancers of the rectum, and 3 
cancers of the digestive organs combined, separately for males 4 
and females 5 
Site (ICD-7; ICD-10) Total 
effect† 
HR (95% CI) 
Natural 
indirect effect† 
HR (95% CI) 
Natural direct 
effect† 




Colon (153; C18) - males 1.23 (1.15 to 
1.30) 
1.04 (1.02 to 
1.06) 
1.18 (1.10 to 
1.26) 
19.3% (8.2% to 
34.8%) 
Colon (153; C18) - 
females 
1.09 (1.03 to 
1.14) 
1.02 (1.00 to 
1.03) 
1.07 (1.02 to 
1.13) 
17.5% (-7.0% to 
58.4%) 
Rectum (154; C19-21) - 
males 
1.12 (1.03 to 
1.20) 
1.03 (1.00 to 
1.06) 
1.08 (0.99 to 
1.17) 
28.5% (2.3% to 
100%) 
Rectum (154; C19-21) - 
females 
1.09 (1.01 to 
1.18) 
1.04 (1.01 to 
1.07) 
1.05 (0.96 to 
1.14) 
46.6% (7.5% to 
100%) 
Digestive organs 
combined‡ - males 
1.23 (1.18 to 
1.28) 
1.04 (1.02 to 
1.05) 
1.19 (1.14 to 
1.23) 
17.4% (10.0% to 
26.5%) 
Digestive organs 
combined‡ - females 
1.11 (1.07 to 
1.15) 
1.03 (1.02 to 
1.05) 
1.08 (1.03 to 
1.12) 
30.4% (17.5% to 
53.0%) 
 6 
†HRs (per 5 kg/m² increase) were estimated according to the 2-stage regression method proposed by 7 
VanderWeele, adjusted for baseline age, smoking status, fasting status, cohort, and decade of birth,  8 
with attained age as the underlying time scale. Analyses were restricted to participants with a BMI≥18.5 9 
(i.e. no underweight). 10 
‡Digestive organs combined include the following sites: oesophagus (adenocarcinoma), colon, rectum, 11 
liver, gallbladder, and pancreas. 12 
HR = hazard ratio; BMI = body mass index; CI = confidence interval; ICD = International Classification 13 
of Diseases. 14 
  15 
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Table S3. Risk of cancer by TyG index and decomposition of the 1 
total effect of continuous BMI on cancer risk into natural direct 2 
and indirect effect mediated by the TyG index, stratified by cancer 3 
site, restricted to individuals with a fasting status of 8h or more 4 
(N=300 121) 5 
Site (ICD-7; ICD-10) HR of TyG 





















1.03 (0.85 to 
1.26) 
1.23 (0.98 to 
1.52) 
1.00 (0.94 to 
1.08) 
1.23 (0.96 to 
1.51) 
- 
Colon (153; C18) 1.08 (1.03 to 
1.13) 
1.11 (1.05 to 
1.16) 
1.03 (1.01 to 
1.05) 
1.07 (1.02 to 
1.13) 
30.5% (12.9% to 
67.3%) 
Rectum (154; C19-21) 1.12 (1.06 to 
1.19) 
1.11 (1.03 to 
1.18) 
1.04 (1.02 to 
1.06) 
1.06 (0.99 to 
1.14) 
38.9% (15.0% to 
100%) 
Liver (155.0; C22) 1.12 (1.02 to 
1.24) 
1.49 (1.33 to 
1.64) 
1.04 (1.00 to 
1.08) 
1.44 (1.28 to 
1.59) 




1.11 (0.97 to 
1.27) 
1.26 (1.09 to 
1.43) 
1.04 (0.99 to 
1.10) 
1.21 (1.04 to 
1.38) 
18.1% (-5.6% to 
62.9%) 
Pancreas (157; C25) 1.12 (1.04 to 
1.21) 
1.13 (1.03 to 
1.24) 
1.04 (1.01 to 
1.07) 
1.09 (0.99 to 
1.20) 
29.3% (6.2% to 
100%) 
Pancreas - males 1.08 (0.98 to 
1.19) 
1.16 (1.00 to 
1.34) 
1.03 (0.97 to 
1.08) 




Pancreas - females 1.18 (1.06 to 
1.32) 
1.12 (0.99 to 
1.23) 
1.05 (1.01 to 
1.09) 





1.03 (0.99 to 
1.08) 
1.06 (1.02 to 
1.10) 
1.01 (1.00 to 
1.02) 
1.05 (1.01 to 
1.10) 
15.8% (-8.5% to 
70.8%) 
Endometrium (172; C54) 1.08 (1.00 to 
1.17) 
1.46 (1.38 to 
1.55) 
1.02 (0.99 to 
1.04) 
1.44 (1.35 to 
1.53) 
4.6% (-2.0% to 
11.0%) 
Ovary (175.0; C56) 0.99 (0.89 to 
1.10) 
1.03 (0.94 to 
1.14) 
0.99 (0.96 to 
1.02) 
1.05 (0.94 to 
1.15) 
- 
Kidney (renal cell) (180.0, 
180.9; C64) 
1.08 (1.01 to 
1.16) 
1.38 (1.27 to 
1.48) 
1.03 (1.00 to 
1.06) 
1.34 (1.24 to 
1.45) 




1.10 (1.07 to 
1.13) 
1.15 (1.11 to 
1.19) 
1.04 (1.02 to 
1.05) 
1.11 (1.07 to 
1.15) 
24.8% (15.7% to 
36.6%) 
Endometrium, ovary and 
postmenopausal breast 
combined 
1.04 (1.00 to 
1.08) 
1.14 (1.11 to 
1.18) 
1.01 (1.00 to 
1.02) 
1.13 (1.10 to 
1.17) 
6.2% (-2.4% to 
15.4%) 
 6 
*HRs were estimated in Cox proportional hazards models adjusted for BMI category, baseline age, sex, 7 
smoking status, cohort, and decade of birth, with attained age as the underlying time scale.  8 
†HRs (per 5 kg/m² increase) were estimated according to the 2-stage regression method proposed by 9 
VanderWeele15, adjusted for baseline age, sex, smoking status, cohort, and decade of birth, with 10 
attained age as the underlying time scale. Analyses were restricted to participants with a BMI≥18.5 (i.e. 11 
no underweight). 12 
30 
 
‡Proportion mediated not given in cases where the null-effect (i.e. 1) is contained in the 95% CI of the 1 
HR of the total effect. 2 
§Adenocarcinomas were identified via information on morphology (ICD-O-3 morphologic key). 3 
¶Digestive organs combined include the following sites: oesophagus (adenocarcinoma), colon, rectum, 4 
liver, gallbladder, and pancreas. 5 
HR = hazard ratio; BMI = body mass index; CI = confidence interval; ICD = International Classification 6 
of Diseases. 7 
  8 
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Table S4. Risk of cancer by TyG index and decomposition of the 1 
total effect of continuous BMI on cancer risk into natural direct 2 
and indirect effect mediated by the TyG index, stratified by cancer 3 
site, restricted to individuals free of diabetes at baseline 4 
(N=323 911; participants of the VHM&PP cohort not included 5 
since information on diabetic status was not captured in the 6 
VHM&PP cohort) 7 
Site (ICD-7; ICD-10) HR of TyG 





















1.18 (0.96 to 
1.45) 
1.59 (1.23 to 
1.95) 
1.05 (0.96 to 
1.14) 
1.51 (1.17 to 
1.88) 
10.1% (-10.1% to 
35.7%) 
Colon (153; C18) 1.09 (1.04 to 
1.15) 
1.16 (1.10 to 
1.23) 
1.04 (1.02 to 
1.06) 
1.12 (1.06 to 
1.19) 
23.1% (10.1% to 
42.5%) 
Rectum (154; C19-21) 1.06 (1.00 to 
1.13) 
1.09 (1.01 to 
1.17) 
1.02 (1.00 to 
1.05) 
1.06 (0.98 to 
1.15) 
27.6% (-8.6% to 
100%) 
Liver (155.0; C22) 1.15 (0.99 to 
1.35) 
1.42 (1.18 to 
1.68) 
1.04 (0.98 to 
1.10) 
1.36 (1.13 to 
1.61) 




1.08 (0.91 to 
1.28) 
1.37 (1.14 to 
1.61) 
1.02 (0.96 to 
1.10) 
1.33 (1.10 to 
1.59) 
7.8% (-16.5% to 
40.6%) 
Pancreas (157; C25) 1.09 (1.01 to 
1.19) 
1.06 (0.95 to 
1.16) 
1.04 (1.01 to 
1.07) 
1.02 (0.91 to 
1.12) 
- 
Pancreas – males 1.06 (0.96 to 
1.17) 
1.11 (0.94 to 
1.28) 
1.03 (0.98 to 
1.07) 
1.11 (0.94 to 
1.28) 
- 
Pancreas - females 1.17 (1.01 to 
1.35) 
1.00 (0.86 to 
1.14) 
1.06 (1.01 to 
1.12) 





1.02 (0.95 to 
1.08) 
1.06 (1.00 to 
1.11) 
1.01 (0.98 to 
1.03) 
1.05 (0.99 to 
1.11) 
13.2% (-60.0% to 
100%) 
Endometrium (172; C54) 1.00 (0.92 to 
1.09) 
1.55 (1.45 to 
1.65) 
0.99 (0.96 to 
1.02) 
1.56 (1.45 to 
1.67) 
-2.3% (-9.3% to 
3.5%) 
Ovary (175.0; C56) 1.03 (0.93 to 
1.14) 
1.10 (0.99 to 
1.21) 
1.00 (0.97 to 
1.04) 
1.09 (0.98 to 
1.21) 
- 
Kidney (renal cell) (180.0, 
180.9; C64) 
1.17 (1.08 to 
1.28) 
1.36 (1.23 to 
1.49) 
1.06 (1.02 to 
1.10) 
1.28 (1.16 to 
1.41) 




1.09 (1.05 to 
1.12) 
1.15 (1.11 to 
1.19) 
1.03 (1.02 to 
1.05) 
1.11 (1.07 to 
1.16) 
22.8% (13.1% to 
36.6%) 
Endometrium, ovary and 
postmenopausal breast 
combined 
1.01 (0.97 to 
1.06) 
1.20 (1.16 to 
1.25) 
1.00 (0.99 to 
1.02) 
1.20 (1.15 to 
1.25) 
0.7% (-8.0% to 
9.2%) 
 8 
*HRs were estimated in Cox proportional hazards models adjusted for BMI category, baseline age, sex, 9 
smoking status, fasting status, cohort, and decade of birth, with attained age as the underlying time 10 
scale. 11 
†HRs (per 5 kg/m² increase) were estimated according to the 2-stage regression method proposed by 12 
VanderWeele15, adjusted for baseline age, sex, smoking status, fasting status, cohort, and decade of 13 
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birth, with attained age as the underlying time scale. Analyses were restricted to participants with a 1 
BMI≥18.5 (i.e. no underweight). 2 
‡Proportion mediated not given in cases where the null-effect (i.e. 1) is contained in the 95% CI of the 3 
HR of the total effect. 4 
§Adenocarcinomas were identified via information on morphology (ICD-O-3 morphologic key). 5 
¶Digestive organs combined include the following sites: oesophagus (adenocarcinoma), colon, rectum, 6 
liver, gallbladder, and pancreas. 7 
HR = hazard ratio; BMI = body mass index; CI = confidence interval; ICD = International Classification 8 
of Diseases. 9 
  10 
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Table S5: Associations of BMI with cancer risk, with and without 1 
adjusting for TyG index, stratified by cancer site 2 





Model 2 (with TyG index) 
Oesophagus (adenocarcinoma‡) (150; C15) 1.48 (1.22 to 1.78) 1.44 (1.18 to 1.76) 
Colon (153; C18) 1.14 (1.09 to 1.19) 1.11 (1.06 to 1.16) 
Rectum (154; C19-21) 1.09 (1.04 to 1.15) 1.06 (1.00 to 1.12) 
Liver (155.0; C22) 1.47 (1.34 to 1.62) 1.42 (1.28 to 1.57) 
Gallbladder (155.1-155.3; C23-24) 1.29 (1.15 to 1.46) 1.25 (1.09 to 1.42) 
Pancreas (157; C25) 1.11(1.04 to 1.19) 1.06 (0.99 to 1.15) 
Pancreas - males 1.17 (1.05 to 1.31) 1.14 (1.01 to 1.28) 
Pancreas - females 1.07 (0.97 to 1.17) 1.01(0.91 to 1.11) 
Breast (postmenopausal) (170; C50) 1.05 (1.01 to 1.09) 1.04 (1.00 to 1.09) 
Endometrium (172; C54) 1.50 (1.43 to 1.57) 1.49 (1.41 to 1.57) 
Ovary (175.0; C56) 1.05 (0.97 to 1.13) 1.06 (0.97 to 1.15) 
Kidney (renal cell) (180.0, 180.9; C64) 1.35 (1.27 to 1.44) 1.30 (1.21 to 1.39) 
Digestive organs combined§ 1.16 (1.12 to 1.19) 1.12 (1.09 to 1.15) 
Endometrium, ovary and breast 
(postmenopausal) combined 
1.16 (1.13 to 1.20) 1.16 (1.12 to 1.19) 
 3 
Model 1: adjusted for baseline age, sex, smoking status, fasting status, cohort, and decade of birth.  4 
Model 2: adjusted for the same variables as in Model 1, plus additionally for TyG index. 5 
Analyses were restricted to participants with a BMI≥18.5 (i.e. no underweight).  6 
†HRs for BMI were estimated in Cox proportional hazards models with attained age as the underlying 7 
time scale and are given per 5 kg/m² increase. 8 
‡Adenocarcinomas were identified via information on morphology (ICD-O-3 morphologic key). 9 
§Digestive organs combined include the following sites: oesophagus (adenocarcinoma), colon, rectum, 10 
liver, gallbladder, and pancreas. 11 
HR = hazard ratio; BMI = body mass index; CI = confidence interval; ICD = International Classification 12 
of Diseases. 13 
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